Hepatitis C drug costs beat alternative: Merck By: CNBC.com News May 07, 2014 at 16:01 PM EDT May the best drug win. That's how Merck Chief Executive Ken Frazier views the rising competition for hepatitis C treatments. Read More >> Related Stocks: AbbVie Bristol-Myers Squibb Gilead Sciences Johnson & Johnson Merck & Co